Body composition as a determinant of the therapeutic index with androgen signaling inhibition-Reference-Cited by-同舟云学术

Body composition as a determinant of the therapeutic index with androgen signaling inhibition

Published:2024-07-17 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Hahn Andrew W.^ORCID,Tidwell Rebecca S.^ORCID,Pilie Patrick G.,Yu Yao,Liu Jingjing,Surasi Devaki Shilpa,Titus Mark,Zhang Jianhua,Venkatesh Neha,Panaretakis Theocharis,Gregg Justin R.,Zurita Amado J.^ORCID,Siddiqui Bilal A.,Corn Paul G.,Subudhi Sumit K.^ORCID,Msaouel Pavlos^ORCID,Koutroumpakis Efstratios^ORCID,Huff Chad D.,Aparicio Ana^ORCID,McQuade Jennifer L.,Frigo Daniel E.^ORCID,Logothetis Christopher J.^ORCID

Funder

Conquer Cancer Foundation

Prostate Cancer Foundation

U.S. Department of Defense

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41391-024-00870-8.pdf

Reference49 articles.

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

3. Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer—A population-based analysis of 2 national cohorts. Cancer. 2018;124:2931–8.

4. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl J Med. 2013;368:1314–25.

5. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700.